n INTRODUCTION I n systemic scleorsis (SSc), the fibrosis of skin and internal organs is an important pathological feature and it is primarily determined by the transition of quiescent to activated fibroblasts, called myofibroblasts, that become effector cells by enhancing the synthesis and deposition of collagens and other extracellular matrix (ECM) macromolecules (1) (2) (3) (4) . Fibrosis is regulated by a complex interaction between cytokines and growth factors, such as transforming growth factor-β (TGF-β) and endothelin-1 (ET-1) which act on different cell types involved in the fibrotic process (pericytes, mesenchymal stem cells, and fibroblasts, in particular) (5, 6) . In a recent study, TGF-β was shown to induce ET-1 expression in human dermal fibroblasts and promoted their differentiation to profibrotic and contractile myofibroblasts, confirming the crucial role of the TGF-β/ET-1 axis in the development summary Endothelin-1 (ET-1) seems to enhance the pro-fibrotic protein synthesis by skin fibroblasts and its effects are mediated by endothelin-A and B (ET A and ET B ) receptors. This study aimed to investigate the effects of ET A and ET B receptor antagonists (ET A RA-sitaxentan and ET A/B RA-bosentan) on type I collagen (COL-1), fibronectin (FN) and fibrillin-1 (FBL-1) synthesis in primary cultures of skin fibroblasts from systemic sclerosis (SSc) patients. Primary cultures of fibroblasts were obtained from skin biopsies of 6 female SSc patients and were treated with ET-1 (100 nM) for 24 and 48 hrs with or without pre-treatment (1 hr) with ET A RA (2 µM) or ET A/ B RA (10 µM). Primary culture of human SSc skin fibroblasts not treated with ET-1 or ET receptor antagonists (ET A RA and ET A/B RA) were used as controls. COL-1, FN and FBL-1 synthesis was evaluated by immunocytochemistry and Western blot analysis. Immunocytochemistry and Western blot analysis showed that ET-1 significantly increased COL-1 and FN synthesis at 24 and 48 hrs and FBL-1 synthesis at 48 hrs vs untreated cells. ET A RA significantly contrasted the ET-1-mediated increase in COL-1 and FN at 24 hrs as well as COL-1 and FBL-1 at 48 hrs, but not FN synthesis vs ET-1-treated fibroblasts. Conversely, ET A/B RA significantly antagonized the ET-1-mediated overproduction of COL-1 and FN both at 24 and 48 hrs and the FBL-1 synthesis at 48 hrs vs ET-1-treated cells. The single ET A RA treatment seems to contrast significantly the increase in COL-1 synthesis, whereas the dual ET A/B RA treatment seems active in significantly antagonizing both COL-1 and FN overproduction induced by ET-1. In conclusion, ET-1 antagonism might have positive effects in contrasting the profibrotic activity of systemic sclerosis skin fibroblasts. 
n MATERIALS AND METHODS

Cell cultures and treatments
Skin biopsies were obtained during diagnostic procedures (Dermatology Clinic, University of Genoa, Italy) from 6 female SSc patients (mean age 64±8 years) after informed consent and Ethical Committee approval were obtained. In order to reduce variability, study participants showed the same level of skin/disease involvement (limited SSc), and average disease duration (4.6±4 years). Ongoing treatments limited to vasodilator drugs (loftyl, iloprost) were stopped at least one month before the diagnostic procedure and subsequently restarted. Skin biopsies were cut, incubated with collagenase 0.1 µg/mL (Sigma-Aldrich, Milan, Italy) and finally plated in cell culture dishes in the presence of culture medium made up of RPMI 1640 at 10% of fetal bovine serum (FBS, Lonza, South America), and 1% penicillin-streptomycin and 1% of L-glutamine (Lonza) at 37°C 5% of CO 2 to obtain skin fibroblasts. The cells were grown in culture medium until the 4 th passage. To detect the optimal concentration able to antagonize the mitogenic effects of ET-1, a concentration range (0.1 µM -100 µM) for ET A RA (sitaxentan) and ET A/B RA (bosentan) was tested before starting with the experiments. The optimal concentration found to reduce the ET-1 effects was 2 µM for ET A RA and 10 µM for ET A/B RA (data not shown), in agreement with other in vitro studies (2, 5) . SSc fibroblasts at the 4 th passage were conditioned with or without pre-treatment for 1 h with ET A RA (2 µM) or ET A/B RA (10 µM) and then treated with ET-1 (100 nM) for 24 and 48 hrs in order to test the effects of the ET receptor antagonists. SSc fibroblasts were also treated with ET A RA (2 µM) and ET A/B RA (10 µM) alone for 24 and 48 hrs. Primary cultures of human SSc skin fibroblasts not treated with ET-1 or ET receptor antagonists (ET A RA and ET A/B RA) were used as controls. Normal fibroblast cultures have been previously tested in our laboratory and were found to be responsive to ET-1 treatment in the same way as SSc fibroblasts (6) . For ethical reasons, in this in vitro study, new biopsies from healthy subjects were not performed.
Immunocytochemistry
SSc fibroblasts at the 4 th passage were cultured in Flexi PERM chamber slides (1x10 4 cells/spot) and treated according to the experimental design. At the end of treatment, the cells were incubated with primary antibodies to human FN (dilution 1:100, Sigma-Aldrich), COL-1 (dilution 1:100, Abcam, Cambridge, UK) and FBL-1 (dilution 1:100, Millipore, Billerica, MA, USA). Linked antibodies were detected by biotinylated universal secondary antibody and subsequently with horseradishperoxydase-streptavidine complex (Vector Laboratories, Burlingame, CA, USA). The slide evaluation was performed on 30 light power fields for each condition by light microscopy (magnification 40X) and computerized image analysis with Leica Q500MC Image Analysis System (Leica, Cambridge, UK).
Western blot analysis
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Effects of ET-1 on ECM protein synthesis
Results showed that ET-1 significantly increased COL-1 and FN synthesis both at 24 and 48 hrs (P<0.001 for every protein) vs untreated fibroblasts ( Fig. 1 and 2 ). ET-1 was able to increase the FBL-1 synthesis after 48 hrs of treatment (P<0.001), whereas no difference was observed at 24 hrs vs untreated fibroblasts (Fig. 3) . These data were obtained by immunocytochemistry and relative image analysis. COL-1, FN and FBL-1 synthesis was also investigated by Western blotting and relative densitometric analysis. Results showed that ET-1 was able to induce a statistically significant increase in COL-1 and FN synthesis both at 24 hrs (P<0.01 for both) and 48 hrs (P<0.05 for both) vs untreated fibroblasts (Fig. 4) . Finally, FBL-1 production was found significantly increased only at 48 hrs by ET-1 treatment vs untreated fibroblasts (P<0.05) (Fig. 4B) . original article both) synthesis, whereas no significant difference was observed in FBL-1 synthesis vs ET-1-treated fibroblasts (Fig. 1A, 2A and  3A) . At 48 hrs, ET A RA still significantly contrasted the increase in COL-1 and FBL-1 synthesis induced by ET-1 (P<0.01 and P<0.001, respectively), but it lost any effect on FN synthesis vs ET-1-treated cells (Fig.  1B, 2B and 3B) . On the contrary, at 48 hrs ET A/B RA still significantly antagonized the ET-1-mediated increase in all the investigated ECM protein synthesis (P<0.05 for COL-1; P<0.01 for FN; P<0.001 for FBL-1 vs ET-1-treated fibroblasts) (Fig. 1B, 2B and 3B). The effect of ET A/B RA treatment on FN was found sustained also at 72 hrs (data not shown). These data were obtained by immunocytochemistry and relative image analysis. Western blotting analysis confirmed the results observed by immunocytochemistry showing that both ET A RA and ET A/B RA significantly antagonized COL-1 (P<0.01 and P<0.05, respectively) and FN synthesis induced by ET-1 (P<0.001 and P<0.05, respectively) at 24 hrs vs ET-1-treated fibroblasts ( Figure 4A ). At 48 hrs, ET A RA contrasted the ET-1-mediated increase in both COL-1 and FBL-1 synthesis (P<0.05 and P<0.01, respectively) whereas no difference was observed for FN vs ET-1-treated fibroblasts ( Figure 4B ). Conversely, ET A/B RA maintained the ability to antagonize the increase in synthesis of all the investigated ECM proteins induced by ET-1 also at 48 hrs of treatment vs ET-1-treated cells (P<0.05 for COL-1 and FN; P<0.01 for FBL-1) ( Figure  4B ). The effect of ET A/B RA treatment on FN was found sustained also at 72 hrs (data not shown). The SSc skin fibroblasts were also treated with ET A RA or ET A/B RA alone and it was shown that both ET receptor antagonists reduced COL-1 and FN synthesis, especially after 24 hrs, and FBL-1 synthesis at 48 hrs, but this was not statistically significant (data not shown).
Effects of ET receptor antagonists on ECM protein synthesis
n DISCUSSION Finally, the analysis of FBL-1 showed that ET-1 increased the synthesis of this protein and this increase was temporarily secondary to the COL-1 and FN. As we know, FBL-1 is the main component of ECM microfibrils and plays an important role on the profibrotic phenotype of SSc fibroblasts (17) . As observed for COL-1 and FN, the ET A RA and ET A/B RA contrasted significantly with the increase in FBL-1 synthesis induced by ET-1, an effect that might be the consequence of a general downregulation of the ECM synthesis exerted by these antagonists.
In agreement with these results, a recent study showed that in SSc, dermal fibroblasts the microfibril abnormalities might be a secondary event of matrix deregulation and in ECM remodeling, probably due to the alteration of proteolitic process induced by growth factors (i.e., TGF-β) that characterize the SSc fibrotic process (18) .
n CONCLUSIONS
In conclusion, in vitro interference of the ET receptor antagonism with the ECM protein synthesis and the resultant possible therapeutic effect on progressive fibrosis, suggest that ET antagonism agents could act as potential disease modifying molecules in combination therapies for SSc (18) .
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